Neumora Therapeutics (NMRA) Q4 2024 earnings summary

Executive summary

• Leadership transition in early 2024 with new CEO, president, COO, and CFO, all emphasizing commitment to advancing novel therapies for brain diseases and leveraging a pipeline of seven neuroscience programs, including two clinical-stage assets.

• The company is focused on delivering transformative medicines for major depressive disorder (MDD), Alzheimer's disease agitation, and other prevalent brain diseases, with a robust clinical and preclinical pipeline.

• Advanced seven neuroscience programs, with key data readouts expected in 2025–2026.

• Strong cash position of $307.6 million as of December 31, 2024, supporting operations into mid-2026.

Financial highlights

• Total operating expenses for Q4 2024 were $58.8 million, down from $108.7 million in Q4 2023.

• Full-year 2024 operating expenses were $243.8 million, up from $235.9 million in 2023, mainly due to increased R&D activities for the phase three navacaprant program and portfolio growth.

• R&D expenses rose to $45.9 million in Q4 2024 and $200.9 million for FY 2024, mainly due to clinical trial advancement.

• G&A expenses increased to $17.0 million in Q4 2024 and $62.5 million for FY 2024, driven by personnel and professional services.

• Net loss was $58.8 million for Q4 2024 and $243.8 million for FY 2024.

Outlook and guidance

• Cash runway expected to fund operations into mid-2026.

• Top-line data from KOASTAL-3 (navacaprant in MDD) expected in Q1 2026 and KOASTAL-2 in Q2 2026.

• Phase 1b data for NMRA-511 in Alzheimer's agitation anticipated by end of 2025.

• Next M4 compound to enter the clinic by mid-2025, with updates on the M4 franchise expected at that time.